Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Selexis SA , a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, announced today that they have...
NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers
First IND for NexImmune’s AIM nanoparticle platform in solid tumorsIND clearance enables commencement of a clinical trial to evaluate NEXI-003, an...
Legend Capital Portfolio: Japan's NO.1 VTuber Operator ANYCOLOR Lists on the Tokyo Stock Exchange
HONG KONG, Jun 9, 2022 - (ACN Newswire) - On June 8th 2022, Legend Capital's portfolio company ANYCOLOR, a leading Virtual YouTuber (VTuber) management company in Japan, was listed on the Tokyo Stock Exchange....